Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Joseph H. Antin, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chief, Stem Cell Transplantation, Emeritus
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Aplastic anemia
  • Bone marrow failure
  • Graft-versus-host disease and Graft-versus-leukemia
  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Stem cell/bone marrow transplantation

Diseases Treated

  • Allogeneic Stem Cell Transplant

Contact Information

  • Appointments617-632-5138 (new)
    617-632-3470 (follow-up)
  • Office Phone Number617-632-2525
  • Fax617-632-4422

Bio

Dr. Antin received his MD from Cornell University in 1978, and postgraduate training in hematology and medical oncology at DFCI and Brigham and Women's Hospital. He subsequently served as director of the Bone Marrow Transplantation Service at BWH from 1987 to 1997. He now heads the Stem Cell Transplant Program of the Department of Medical Oncology at DFCI and BWH. He is a founding member and past president of the American Society of Blood and Marrow Transplantation and a past Chairman of the Steering Committee of the BMT Clinical Trial Network.

Board Certification:

  • Hematology, 1984
  • Internal Medicine, 1981
  • Medical Oncology, 1983

Fellowship:

  • Brigham and Women's Hospital, Hematology
  • Dana-Farber Cancer Institute, Oncology

Residency:

  • Peter Bent Brigham Hospital/Harvard Medical School, Internal Medicine

Medical School:

  • Weill Medical College of Cornell University

Research

Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect

The biology of acute graft-versus-host disease (GVHD) must be considered in the context of a host that has been injured by the underlying disease, conditioning regimen, and infection. These factors result in an environment that supports and sustains the clinical syndrome of acute GVHD through induction of inflammatory mediators such as chemokines, adhesion molecules, cytokines, and cellular effectors. If this cycle can be interrupted, GVHD might be ameliorated. Thus we are studying novel regimens to control GVHD, through both cellular engineering and application of new immunosuppressants, including sirolimus and denileukin diftitox.A second related interest is to understand and harness the graft-versus-leukemia (GVL) effect. Previous efforts to control GVHD, such as T cell depletion, have resulted in loss of GVL effect. Inhibition of inflammatory cytokines may result in reductions in GVHD with sparing of GVL effect. Furthermore, we have shown that we can use GVL effect to induce remissions in relapsed patients, but at the risk of inducing GVHD. We are studying whether the limitations of T cell depletion can be overcome with the judicious use of donor lymphocytes preemptively administered after transplantation. We are also assessing whether GVL effect can be harnessed to allow a reduction in transplantation conditioning and its associated toxicity.

Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 Aug 26.
View in: PubMed

SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. Hum Mutat. 2021 Jul 23.
View in: PubMed

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021 07 22; 138(3):273-282.
View in: PubMed

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 Jun 10; 137(23):3212-3217.
View in: PubMed

The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood. 2021 May 21.
View in: PubMed

Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217.
View in: PubMed

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. 2021 Apr 13.
View in: PubMed

GVHD Prophylaxis 2020. Front Immunol. 2021; 12:605726.
View in: PubMed

Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223.
View in: PubMed

Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7.
View in: PubMed

Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2021 05; 27(5):433.e1-433.e8.
View in: PubMed

COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871.
View in: PubMed

Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
View in: PubMed

Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021 01 21; 137(3):420-428.
View in: PubMed

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020 12 24; 136(26):3070-3081.
View in: PubMed

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175.
View in: PubMed

Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012.
View in: PubMed

Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
View in: PubMed

Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). Blood. 2020 Aug 31.
View in: PubMed

Short Telomere Length Predicts Non-Relapse Mortality after Stem Cell Transplantation for Myelodysplastic Syndrome. Blood. 2020 Aug 17.
View in: PubMed

Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. Biol Blood Marrow Transplant. 2020 08; 26(8):1446-1451.
View in: PubMed

BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893.
View in: PubMed

Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020 06 20; 38(18):2062-2076.
View in: PubMed

Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. Expert Rev Hematol. 2020 05; 13(5):519-532.
View in: PubMed

Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2020 09; 55(9):1844-1846.
View in: PubMed

Burden of illness among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: a multicenter retrospective chart review study. Ann Hematol. 2020 Apr; 99(4):743-752.
View in: PubMed

Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2020 05; 26(5):e94-e100.
View in: PubMed

The role of regulatory T cells in graft-versus-host disease management. Expert Rev Hematol. 2020 02; 13(2):141-154.
View in: PubMed

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood. 2020 01 09; 135(2):97-107.
View in: PubMed

Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
View in: PubMed

Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. JAMA Oncol. 2020 Jan 01; 6(1):e192974.
View in: PubMed

Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020 04; 26(4):798-804.
View in: PubMed

Follistatin and Soluble Endoglin Predict 1-Year Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):606-611.
View in: PubMed

Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539.
View in: PubMed

Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019 10 22; 3(20):3123-3131.
View in: PubMed

A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
View in: PubMed

Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplant. 2020 09; 55(9):1821-1823.
View in: PubMed

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561.
View in: PubMed

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019 12; 25(12):2383-2387.
View in: PubMed

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204.
View in: PubMed

Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Biol Blood Marrow Transplant. 2019 11; 25(11):2143-2151.
View in: PubMed

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
View in: PubMed

Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clin Immunol. 2019 10; 207:18-23.
View in: PubMed

Positive psychological experiences in allogeneic hematopoietic stem cell transplantation. Psychooncology. 2019 08; 28(8):1633-1639.
View in: PubMed

Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1744-1755.
View in: PubMed

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994.
View in: PubMed

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979.
View in: PubMed

Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
View in: PubMed

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar; 6(3):e132-e143.
View in: PubMed

Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respir Res. 2019 Jan 21; 20(1):15.
View in: PubMed

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
View in: PubMed

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2019 03; 25(3):488-495.
View in: PubMed

Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85.
View in: PubMed

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):137-144.
View in: PubMed

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. 2018 10; 103(10):1708-1719.
View in: PubMed

Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. Biol Blood Marrow Transplant. 2018 10; 24(10):2164-2165.
View in: PubMed

Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Adv. 2018 06 12; 2(11):1272-1276.
View in: PubMed

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; 65(10):e27269.
View in: PubMed

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018 06; 181(6):816-827.
View in: PubMed

Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353.
View in: PubMed

Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9.
View in: PubMed

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Apr 10; 24(4):526.
View in: PubMed

A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740.
View in: PubMed

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845.
View in: PubMed

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 03; 24(3):282-291.
View in: PubMed

a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379.
View in: PubMed

Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530.
View in: PubMed

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018 06; 24(6):1274-1280.
View in: PubMed

Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 03; 24(3):514-520.
View in: PubMed

Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14; 1(24):2269-2279.
View in: PubMed

Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899.
View in: PubMed

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402. Bone Marrow Transplant. 2018 01; 53(1):64-68.
View in: PubMed

Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2017 Oct 10; 1(22):1919-1922.
View in: PubMed

Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep; 124(3):253-260.
View in: PubMed

An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017 Jun 15; 2(12).
View in: PubMed

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402. Bone Marrow Transplant. 2017 Sep; 52(9):1300-1303.
View in: PubMed

Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; 130(1):91-94.
View in: PubMed

Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017 07; 178(1):112-118.
View in: PubMed

ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. Blood Adv. 2017 Mar 28; 1(9):573-576.
View in: PubMed

Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017 07; 102(7):1185-1191.
View in: PubMed

Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017 07; 102(7):1291-1298.
View in: PubMed

Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017 05; 102(5):958-966.
View in: PubMed

Relationship Between Intestinal Bacteria and the Anticancer Effect of Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 05 20; 35(15):1636-1637.
View in: PubMed

Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Marrow Transplant. 2017 Jun; 23(6):997-1004.
View in: PubMed

Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-ß production. Blood. 2017 05 04; 129(18):2570-2580.
View in: PubMed

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 02 09; 376(6):536-547.
View in: PubMed

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197.
View in: PubMed

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388.
View in: PubMed

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
View in: PubMed

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
View in: PubMed

Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. Blood. 2017 01 12; 129(2):162-170.
View in: PubMed

Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278.
View in: PubMed

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. Biol Blood Marrow Transplant. 2017 01; 23(1):126-133.
View in: PubMed

Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; 23(1):113-118.
View in: PubMed

Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biol Blood Marrow Transplant. 2017 01; 23(1):103-112.
View in: PubMed

Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850.
View in: PubMed

An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091.
View in: PubMed

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2016 10; 22(10):1808-1815.
View in: PubMed

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
View in: PubMed

Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
View in: PubMed

Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7.
View in: PubMed

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259.
View in: PubMed

Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 09; 22(9):1636-1645.
View in: PubMed

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 10; 122(19):3005-3014.
View in: PubMed

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. Br J Haematol. 2017 09; 178(5):816-819.
View in: PubMed

Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 11; 51(11):1504-1506.
View in: PubMed

Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9.
View in: PubMed

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7.
View in: PubMed

Emerging drugs for graft-versus-host disease. Expert Opin Emerg Drugs. 2016 Jun; 21(2):209-18.
View in: PubMed

Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
View in: PubMed

Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97.
View in: PubMed

An interactive video-based approach to diet education for patients posthematopoietic stem cell transplantation. J Clin Oncol. 2016 Mar; 34(7_suppl):183.
View in: PubMed

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016 05 19; 127(20):2427-38.
View in: PubMed

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65.
View in: PubMed

Cord blood versus haploidentical stem cell transplantation for hematological malignancies. Semin Hematol. 2016 Apr; 53(2):98-102.
View in: PubMed

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505.
View in: PubMed

The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016 Apr; 173(1):96-104.
View in: PubMed

Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8.
View in: PubMed

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57.
View in: PubMed

The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016 Jan 14; 127(2):260-7.
View in: PubMed

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 Sep; 2(9):e367-75.
View in: PubMed

IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS One. 2015; 10(7):e0132564.
View in: PubMed

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.
View in: PubMed

Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100(9):1222-7.
View in: PubMed

A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13.
View in: PubMed

Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1776-82.
View in: PubMed

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1583-8.
View in: PubMed

Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
View in: PubMed

The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT. J Natl Compr Canc Netw. 2015 Feb; 13(2):184-9.
View in: PubMed

Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80.
View in: PubMed

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015 Apr; 21(4):761-7.
View in: PubMed

Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clin Cancer Res. 2015 Mar 01; 21(5):1010-8.
View in: PubMed

Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transplant. 2015 Apr; 21(4):640-5.
View in: PubMed

Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015 Mar; 21(3):509-16.
View in: PubMed

Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015 May 01; 21(9):2020-8.
View in: PubMed

Readmissions following umbilical cord blood stem cell transplantation. J Clin Oncol. 2014 Oct 20; 32(30_suppl):272.
View in: PubMed

Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24.
View in: PubMed

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76.
View in: PubMed

Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol. 2014 Dec; 89(12):1097-101.
View in: PubMed

Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. 2015 Jan; 21(1):55-9.
View in: PubMed

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8.
View in: PubMed

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014 Nov 20; 124(22):3221-7; quiz 3335.
View in: PubMed

Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6.
View in: PubMed

Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica. 2014 Dec; 99(12):1868-75.
View in: PubMed

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
View in: PubMed

A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43.
View in: PubMed

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014 Aug 21; 124(8):1372-7.
View in: PubMed

Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1717-21.
View in: PubMed

Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014 Jul 17; 124(3):334-43.
View in: PubMed

Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21.
View in: PubMed

Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
View in: PubMed

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
View in: PubMed

Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1248-51.
View in: PubMed

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014 Jun 05; 123(23):3664-71.
View in: PubMed

Allotransplantation for patients age =40 years with non-Hodgkin lymphoma: encouraging progression-free survival. Biol Blood Marrow Transplant. 2014 Jul; 20(7):960-8.
View in: PubMed

White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7.
View in: PubMed

Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014 Apr; 89(4):404-9.
View in: PubMed

Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75.
View in: PubMed

BK virus disease after allogeneic stem cell transplantation: a cohort analysis. Biol Blood Marrow Transplant. 2014 Apr; 20(4):564-70.
View in: PubMed

Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ß-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J. 2014 Jan 17; 4:e178.
View in: PubMed

Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome. J Neuropsychiatry Clin Neurosci. 2014; 26(3):249-57.
View in: PubMed

Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014 Feb; 20(2):285-7.
View in: PubMed

Steroid-refractory acute graft-versus-host disease: is there an effective therapy? Biol Blood Marrow Transplant. 2014 Feb; 20(2):146-8.
View in: PubMed

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
View in: PubMed

Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1713-8.
View in: PubMed

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81.
View in: PubMed

Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 Aug 08; 369(6):517-28.
View in: PubMed

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39.
View in: PubMed

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
View in: PubMed

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7.
View in: PubMed

Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80.
View in: PubMed

Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1238-43.
View in: PubMed

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
View in: PubMed

Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43.
View in: PubMed

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7.
View in: PubMed

Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013 May-Jun; 58(3):233-51.
View in: PubMed

Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis. 2013 Jun 15; 207(12):1888-97.
View in: PubMed

Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11.
View in: PubMed

Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71.
View in: PubMed

KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013 Jul; 48(7):1000-2.
View in: PubMed

Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients. J Clin Oncol. 2012 Dec; 30(34_suppl):185.
View in: PubMed

Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med. 2013 Feb; 107(2):276-83.
View in: PubMed

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90.
View in: PubMed

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9.
View in: PubMed

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8.
View in: PubMed

Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012 Aug; 3(4):253-65.
View in: PubMed

Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
View in: PubMed

A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13.
View in: PubMed

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):146-7.
View in: PubMed

Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1638-48.
View in: PubMed

Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1462-5.
View in: PubMed

Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul; 18(7):1007-11.
View in: PubMed

Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun; 87(6):569-72.
View in: PubMed

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep; 18(9):1446-54.
View in: PubMed

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55.
View in: PubMed

Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
View in: PubMed

Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
View in: PubMed

Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12.
View in: PubMed

Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012 Jan 05; 119(1):296-307.
View in: PubMed

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec; 12(13):1195-203.
View in: PubMed

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7.
View in: PubMed

The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 May; 18(5):708-15.
View in: PubMed

Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30.
View in: PubMed

Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 2011 Sep 01; 365(9):815-24.
View in: PubMed

A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg. 2011 Sep; 128(3):112e-118e.
View in: PubMed

Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood. 2011 Oct 20; 118(16):4472-9.
View in: PubMed

Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74.
View in: PubMed

Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011 Aug 15; 92(3):359-65.
View in: PubMed

Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83.
View in: PubMed

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb; 18(2):280-8.
View in: PubMed

American journal of cancer research: editorial board (2011). Am J Cancer Res. 2011; 1(6):817-22.
View in: PubMed

Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011 Sep 01; 118(9):2618-21.
View in: PubMed

T-cell depletion in GVHD: less is more? Blood. 2011 Jun 09; 117(23):6061-2.
View in: PubMed

Vaginal bleeding in women with leukemia. J Clin Oncol. 2011 May 20; 29(15_suppl):6577.
View in: PubMed

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011 Jun 16; 117(24):6714-20.
View in: PubMed

Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91.
View in: PubMed

(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9.
View in: PubMed

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011 Jul; 22(7):1608-1613.
View in: PubMed

Invasive fungal disease after remote inoculation in transplant recipients. Clin Infect Dis. 2011 Jan 01; 52(1):e7-10.
View in: PubMed

Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204.
View in: PubMed

Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010 Dec; 85(12):967-71.
View in: PubMed

Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011 Feb 17; 117(7):2275-83.
View in: PubMed

Launching of American Journal of Cancer Research. Am J Cancer Res. 2011; 1(1):i.
View in: PubMed

Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Curr Opin Hematol. 2010 Nov; 17(6):500-4.
View in: PubMed

Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011 Mar; 17(3):291-9.
View in: PubMed

Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Mar; 17(3):434-8.
View in: PubMed

Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8.
View in: PubMed

Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):852-60.
View in: PubMed

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503.
View in: PubMed

Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67.
View in: PubMed

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood. 2010 Jul 22; 116(3):366-74.
View in: PubMed

Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May; 120(5):1479-93.
View in: PubMed

Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica. 2010 Mar; 95(3):364-6.
View in: PubMed

Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5.
View in: PubMed

Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31.
View in: PubMed

Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51.
View in: PubMed

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17.
View in: PubMed

Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant. 2010 Nov; 45(11):1611-7.
View in: PubMed

Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
View in: PubMed

Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800.
View in: PubMed

The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jan 01; 16(1):S1.
View in: PubMed

Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS). Am J Drug Alcohol Abuse. 2010 Jan; 36(1):1-6.
View in: PubMed

Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009 Dec; 41(12):1341-4.
View in: PubMed

Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S18-27.
View in: PubMed

Mental status changes after hematopoietic stem cell transplantation. Cancer. 2009 Oct 01; 115(19):4625-35.
View in: PubMed

Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68.
View in: PubMed

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9.
View in: PubMed

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):15825-30.
View in: PubMed

Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1475-8.
View in: PubMed

Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1066-76.
View in: PubMed

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009 Jul; 15(7):844-50.
View in: PubMed

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61.
View in: PubMed

Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009 Jun; 145(6):816-24.
View in: PubMed

HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009 Apr 01; 27(10):1644-52.
View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009 Feb; 15(2):137-72.
View in: PubMed

Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16; 113(16):3865-74.
View in: PubMed

High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002.
View in: PubMed

Health psychology and distress after haematopoietic stem cell transplantation. Eur J Cancer Care (Engl). 2009 Jan; 18(1):57-63.
View in: PubMed

Biology and management of acute graft-versus-host disease. Cancer Treat Res. 2009; 144:257-75.
View in: PubMed

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009 Mar 26; 113(13):3110-8.
View in: PubMed

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
View in: PubMed

Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol. 2008 Oct; 1(1):111.
View in: PubMed

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31.
View in: PubMed

Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008 Aug; 14(8):920-6.
View in: PubMed

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Oct 15; 112(8):3500-7.
View in: PubMed

The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood. 2008 Oct 15; 112(8):3073-81.
View in: PubMed

Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
View in: PubMed

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
View in: PubMed

Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008 Feb; 14(2):197-207.
View in: PubMed

Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Jan; 14(1):110-5.
View in: PubMed

Novel drugs for the prevention and treatment of acute GVHD. Curr Pharm Des. 2008; 14(20):1962-73.
View in: PubMed

HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008 Feb; 14(2):187-96.
View in: PubMed

A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35.
View in: PubMed

Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9.
View in: PubMed

Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1268-85.
View in: PubMed

Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov; 139(3):504-7.
View in: PubMed

High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15; 13(20):6107-14.
View in: PubMed

Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007 Jul 10; 69(2):156-65.
View in: PubMed

Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007 Aug; 40(3):209-17.
View in: PubMed

Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2007 May; 13(5):505-16.
View in: PubMed

Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007 Jul; 13(7):838-43.
View in: PubMed

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 01; 109(7):3108-14.
View in: PubMed

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007 Jul 15; 110(2):490-500.
View in: PubMed

Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
View in: PubMed

Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007 May 15; 109(10):4586-8.
View in: PubMed

Reduced-Intensity Stem Cell Transplantation: "...whereof a little More than a little is by much too much." King Henry IV, part 1, I, 2. Hematology Am Soc Hematol Educ Program. 2007; 47-54.
View in: PubMed

Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9.
View in: PubMed

Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
View in: PubMed

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64.
View in: PubMed

The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. Curr Hematol Malig Rep. 2006 Sep; 1(3):160-7.
View in: PubMed

Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient. Nat Clin Pract Nephrol. 2006 Sep; 2(9):535-9; quiz 540.
View in: PubMed

Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006 Aug; 38(4):305-10.
View in: PubMed

HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 May; 37(9):845-50.
View in: PubMed

Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):552-9.
View in: PubMed

Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62.
View in: PubMed

Chronic graft-versus-host disease. Curr Opin Oncol. 2006 Mar; 18(2):126-31.
View in: PubMed

Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol. 2006; 19(4):737-55.
View in: PubMed

The clinical spectrum of acute graft-versus-host disease. Semin Hematol. 2006 Jan; 43(1):24-31.
View in: PubMed

Approaches to graft-vs-host disease. Pediatr Transplant. 2005 Dec; 9 Suppl 7:71-5.
View in: PubMed

An overview of hematopoietic stem cell transplantation. Clin Chest Med. 2005 Dec; 26(4):517-27, v.
View in: PubMed

Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15; 106(10):3639-45.
View in: PubMed

Donor leukocyte infusions and graft-versus-malignancy. J Clin Apher. 2005 Jul; 20(2):113-6.
View in: PubMed

Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Jul; 11(7):551-7.
View in: PubMed

Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15; 106(8):2903-11.
View in: PubMed

Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case report. Cancer Immun. 2005 May 19; 5:7.
View in: PubMed

Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005 Aug 15; 106(4):1495-500.
View in: PubMed

Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005 May; 11(5):383-8.
View in: PubMed

Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22.
View in: PubMed

Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005 Mar; 11(3):261-2.
View in: PubMed

Immune reconstitution: the major barrier to successful stem cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2 Suppl 2):43-5.
View in: PubMed

Psychosocial function after hematopoietic stem cell transplantation. Psychosomatics. 2005 Jan-Feb; 46(1):34-40.
View in: PubMed

Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83.
View in: PubMed

Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8.
View in: PubMed

Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant. 2004 Dec; 34(11):987-94.
View in: PubMed

Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005 Feb 15; 105(4):1408-16.
View in: PubMed

Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004 Oct; 10(10):655-68.
View in: PubMed

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4.
View in: PubMed

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004 Sep 15; 101(6):1478; author reply 1478.
View in: PubMed

Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004 Sep; 34(6):471-6.
View in: PubMed

Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics. 2004 Sep-Oct; 45(5):378-85.
View in: PubMed

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
View in: PubMed

Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome. Cancer. 2004 Aug 15; 101(4):782-9.
View in: PubMed

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71.
View in: PubMed

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004 Sep 01; 104(5):1559-64.
View in: PubMed

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004 May; 10(5):328-36.
View in: PubMed

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104(4):1224-6.
View in: PubMed

Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr 19; 199(8):1133-42.
View in: PubMed

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 Jul 15; 104(2):579-85.
View in: PubMed

Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61.
View in: PubMed

Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003 Dec; 9(12):760-5.
View in: PubMed

Stem cell transplantation-harnessing of graft-versus-malignancy. Curr Opin Hematol. 2003 Nov; 10(6):440-4.
View in: PubMed

Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 01; 103(1):353-9.
View in: PubMed

CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. Blood. 2004 Jan 15; 103(2):740-2.
View in: PubMed

A 41-year-old woman with chronic myelogenous leukemia. JAMA. 2003 Aug 27; 290(8):1083-90.
View in: PubMed

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003 Oct 15; 102(8):2768-76.
View in: PubMed

Optimistic expectations and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003 Jun; 9(6):389-96.
View in: PubMed

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82.
View in: PubMed

Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5.
View in: PubMed

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003 Aug 01; 102(3):802-9.
View in: PubMed

Symptoms of pain and depression in related marrow donors: changes after transplant. Psychosomatics. 2003 Jan-Feb; 44(1):59-64.
View in: PubMed

Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002 Oct 15; 100(8):2697-702.
View in: PubMed

Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6.
View in: PubMed

A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 Jan 01; 101(1):363-9.
View in: PubMed

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43.
View in: PubMed

Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002 Dec 15; 100(13):4367-71.
View in: PubMed

Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 2002 Nov 15; 100(10):3479-82.
View in: PubMed

Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002 Jul 15; 100(2):406-14.
View in: PubMed

Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 2002 Jul 15; 74(1):49-54.
View in: PubMed

Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 2002 Jul 04; 347(1):36-42.
View in: PubMed

Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol. 2002 Apr 15; 20(8):2118-26.
View in: PubMed

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002 Mar 15; 99(6):1971-7.
View in: PubMed

A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(5):373-7.
View in: PubMed

Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32.
View in: PubMed

Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(8):444-52.
View in: PubMed

Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002; 8(6):295-302.
View in: PubMed

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7.
View in: PubMed

A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002; 8(1):32-9.
View in: PubMed

The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood. 2001 Dec 01; 98(12):3205-11.
View in: PubMed

Gliomas arising in organ transplant recipients: an unrecognized complication of transplantation? Neurology. 2001 Oct 23; 57(8):1486-8.
View in: PubMed

Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001 Oct 01; 98(7):2043-51.
View in: PubMed

Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol. 2001 Aug 15; 19(16):3685-91.
View in: PubMed

A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001 Jul; 28(2):187-96.
View in: PubMed

Acute graft-versus-host disease: inflammation run amok? J Clin Invest. 2001 Jun; 107(12):1497-8.
View in: PubMed

Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA. 2001 Feb 28; 285(8):1034-8.
View in: PubMed

CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9.
View in: PubMed

Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma. 2001 Feb; 40(5-6):499-509.
View in: PubMed

Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):223-9.
View in: PubMed

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):230-8.
View in: PubMed

Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2001; 7(9):473-85.
View in: PubMed

Peripheral blood stem cells for allogeneic transplantation: a review. Stem Cells. 2001; 19(2):108-17.
View in: PubMed

Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol. 2001 Jan 01; 19(1):242-52.
View in: PubMed

Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000 Dec 15; 96(13):4096-102.
View in: PubMed

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000 Sep 15; 96(6):2062-8.
View in: PubMed

A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15; 95(8):2530-5.
View in: PubMed

Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 2000 Apr 01; 95(7):2219-25.
View in: PubMed

Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood. 2000 Feb 15; 95(4):1214-21.
View in: PubMed

Predicting costs of stem-cell transplantation. J Clin Oncol. 2000 Jan; 18(1):64-71.
View in: PubMed

Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000; 6(1):35-43.
View in: PubMed

Pancreatitis during therapy of acute myeloid leukemia: cytarabine related? Ann Oncol. 1999 Nov; 10(11):1373-6.
View in: PubMed

ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity. Transfusion. 1999 Nov-Dec; 39(11-12):1273-4.
View in: PubMed

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999 Apr; 17(4):1234.
View in: PubMed

Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999 Feb; 17(2):561-8.
View in: PubMed

ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion. 1999 Feb; 39(2):179-87.
View in: PubMed

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999; 5(4):253-61.
View in: PubMed

The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med. 1999; 50:369-86.
View in: PubMed

The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998 Dec 01; 92(11):4047-52.
View in: PubMed

A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 1998 Dec 01; 92(11):4066-71.
View in: PubMed

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998 Oct 01; 92(7):2303-14.
View in: PubMed

Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant. 1998 Oct; 22(8):735-41.
View in: PubMed

Initial therapy for chronic myelogenous leukemia: playing the odds. J Clin Oncol. 1998 Sep; 16(9):2897-903.
View in: PubMed

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44.
View in: PubMed

Relationship of Bcl-2 expression with apoptosis and proliferation in colonic graft versus host disease. Hum Pathol. 1998 Aug; 29(8):869-75.
View in: PubMed

A comparison of related and unrelated marrow donors. Psychosom Med. 1998 Mar-Apr; 60(2):163-7.
View in: PubMed

Infusion of donor peripheral blood mononuclear cells to treat relapse after transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998 Feb; 12(1):123-50.
View in: PubMed

Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998 Jan 15; 91(2):717-23.
View in: PubMed

Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant. 1998 Jan; 21(1):23-8.
View in: PubMed

Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant. 1998; 4(3):151-6.
View in: PubMed

Cytomegalovirus infection in the colon of bone marrow transplantation patients. Mod Pathol. 1998 Jan; 11(1):29-36.
View in: PubMed

Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation: a pilot study. Am J Med Sci. 1998 Jan; 315(1):4-10.
View in: PubMed

Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med. 1997 Dec 15; 127(12):1080-8.
View in: PubMed

Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology. 1997 Dec; 49(6):1711-4.
View in: PubMed

Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997 Nov; 20(9):737-43.
View in: PubMed

Energy level and sleep quality following bone marrow transplantation. Bone Marrow Transplant. 1997 Oct; 20(8):669-79.
View in: PubMed

Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant. 1997 Jul; 20(1):33-8.
View in: PubMed

High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant. 1997 Jun; 3(2):98-106.
View in: PubMed

Liquid nitrogen freezers: a potential source of microbial contamination of hematopoietic stem cell components. Transfusion. 1997 Jun; 37(6):585-91.
View in: PubMed

Substance abuse and bone marrow transplant. Am J Drug Alcohol Abuse. 1997 May; 23(2):301-8.
View in: PubMed

Treatment of chronic graft-versus-host disease with clofazimine. Blood. 1997 Apr 01; 89(7):2298-302.
View in: PubMed

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997 Feb; 15(2):433-44.
View in: PubMed

Preapheresis peripheral blood CD34+ mononuclear cell counts as predictors of progenitor cell yield. Transfusion. 1997 Jan; 37(1):79-85.
View in: PubMed

Graft-versus-leukemia effect of allogeneic bone marrow transplantation and donor mononuclear cell infusions. Cancer Treat Res. 1997; 77:57-85.
View in: PubMed

Idiopathic thrombocytopenic purpura following allogeneic bone marrow transplantation--treatment with anti-D immunoglobulin. Bone Marrow Transplant. 1997 Jan; 19(2):173-4.
View in: PubMed

Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood. 1996 Dec 15; 88(12):4429-34.
View in: PubMed

Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996 Nov; 18(5):975-80.
View in: PubMed

Non-gingival soft tissue growths after allogeneic marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1127-32.
View in: PubMed

Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1149-55.
View in: PubMed

FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood. 1996 Apr 15; 87(8):3514-9.
View in: PubMed

Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood. 1996 Apr 01; 87(7):3012-8.
View in: PubMed

Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol. 1995 Sep; 165(3):627-31.
View in: PubMed

Quality of life following bone marrow transplantation: findings from a multicentre study. Br J Cancer. 1995 Jun; 71(6):1322-9.
View in: PubMed

'Returning to normal' following bone marrow transplantation: outcomes, expectations and informed consent. Bone Marrow Transplant. 1995 Apr; 15(4):573-81.
View in: PubMed

Adoptive immunotherapy for relapsed leukemia following allogeneic bone marrow transplantation. Leuk Lymphoma. 1995 Apr; 17(3-4):191-7.
View in: PubMed

Improved survival for patients with acute myelogenous leukemia. J Clin Oncol. 1995 Mar; 13(3):560-9.
View in: PubMed

Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood. 1994 Dec 01; 84(11):3974-9.
View in: PubMed

Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci. 1994 Sep; 4(1):12-4; discussion 14-6.
View in: PubMed

Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 1994 Aug 15; 84(4):1342-8.
View in: PubMed

Use of recombinant human erythropoietin in allogeneic bone marrow transplant donor/recipient pairs. Blood. 1994 Apr 01; 83(7):1952-7.
View in: PubMed

Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994 Mar 15; 57(5):677-84.
View in: PubMed

Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994 Jan 13; 330(2):100-6.
View in: PubMed

Cytokines and graft-V-host disease. Prog Clin Biol Res. 1994; 390:193-202.
View in: PubMed

Graft-versus-leukemia: no longer an epiphenomenon. Blood. 1993 Oct 15; 82(8):2273-7.
View in: PubMed

Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol. 1993 May; 11(5):937-42.
View in: PubMed

Treatment of therapy-related acute myelogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin North Am. 1993 Apr; 7(2):477-93.
View in: PubMed

Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood. 1993 Apr 01; 81(7):1940-6.
View in: PubMed

In vitro alloreactivity against host antigens in an adult HLA-mismatched bone marrow transplant recipient despite in vivo host tolerance. Transplantation. 1993 Jan; 55(1):76-82.
View in: PubMed

Cytokine dysregulation and acute graft-versus-host disease. Blood. 1992 Dec 15; 80(12):2964-8.
View in: PubMed

Herpes simplex virus and neutropenia following bone marrow transplantation. Transplantation. 1992 Sep; 54(3):553-5.
View in: PubMed

Long-term cryopreservation of human stem cells. Bone Marrow Transplant. 1992 Jun; 9(6):487-90.
View in: PubMed

Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med. 1992 May 15; 116(10):821-8.
View in: PubMed

Development of Lhermitte's sign after bone marrow transplantation. Cancer. 1992 May 01; 69(9):2262-6.
View in: PubMed

Peripheral blood neutrophils in chronically neutropenic patients respond to granulocyte-macrophage colony-stimulating factor with a specific increase in CR1 expression and CR1 transcription. Blood. 1992 Apr 01; 79(7):1667-71.
View in: PubMed

Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood. 1992 Jan 01; 79(1):276-82.
View in: PubMed

Lymphokine profile in bone marrow transplant recipients. Blood. 1991 Dec 01; 78(11):3076-80.
View in: PubMed

Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood. 1991 Oct 15; 78(8):2139-49.
View in: PubMed

Glutamine-enriched intravenous feedings attenuate extracellular fluid expansion after a standard stress. Ann Surg. 1991 Oct; 214(4):385-93; discussion 393-5.
View in: PubMed

Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991 Jul; 9(7):1215-23.
View in: PubMed

Erythropoietin gene regulation: from the laboratory to the bedside. Contrib Nephrol. 1991; 88:35-45; discussion 46-7.
View in: PubMed

Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood. 1990 Dec 01; 76(11):2354-9.
View in: PubMed

Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol. 1990 Oct; 8(10):1699-706.
View in: PubMed

Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol. 1990 Oct; 8(10):1707-14.
View in: PubMed

Variable effect of recombinant human granulocyte-macrophage colony-stimulating factor on bone marrow fibrosis in patients with myelodysplasia. Exp Hematol. 1990 May; 18(4):266-70.
View in: PubMed

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990 Apr; 8(4):648-56.
View in: PubMed

Use of polymerase chain reaction-detected sequence polymorphisms to document engraftment following allogeneic bone marrow transplantation. Transplantation. 1990 Apr; 49(4):714-20.
View in: PubMed

Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood. 1990 Apr 01; 75(7):1426-32.
View in: PubMed

Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Prog Clin Biol Res. 1990; 333:207-15.
View in: PubMed

Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood. 1989 Dec; 74(8):2764-8.
View in: PubMed

Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia. Blood. 1989 Aug 01; 74(2):882-5.
View in: PubMed

Flow cytometric surface light chain analysis of lymphocyte-rich effusions. A useful adjunct to cytologic diagnosis. Cancer. 1989 May 15; 63(10):2024-9.
View in: PubMed

Bone marrow progenitor cells induce a regulatory autologous proliferative T lymphocyte response. J Immunol. 1989 Feb 01; 142(3):766-72.
View in: PubMed

Regulation of cytotoxic T lymphocyte-mediated graft rejection following bone marrow transplantation. Transplantation. 1988 Dec; 46(6):835-9.
View in: PubMed

Reversal of infection with Mycobacterium avium intracellulare by treatment with alpha-interferon in a patient with hairy cell leukemia. Ann Intern Med. 1988 Aug 15; 109(4):292-4.
View in: PubMed

Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure. Behring Inst Mitt. 1988 Aug; (83):149-53.
View in: PubMed

Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood. 1988 Aug; 72(2):705-13.
View in: PubMed

Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988 Mar; 71(3):690-6.
View in: PubMed

B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. J Clin Invest. 1987 Aug; 80(2):325-32.
View in: PubMed

Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 1987 Jan; 69(1):187-91.
View in: PubMed

Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986 Nov; 68(5):1114-8.
View in: PubMed

HTLV-III infection after bone marrow transplantation. Blood. 1986 Jan; 67(1):160-3.
View in: PubMed

Leu-1+ (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotypic and functional studies. J Immunol. 1986 Jan; 136(2):505-10.
View in: PubMed

Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985 Dec; 66(6):1247-50.
View in: PubMed

Acute leukemias, myelodysplasia, and lymphomas. Clin Geriatr Med. 1985 Nov; 1(4):795-826.
View in: PubMed

Phenotype of recovering lymphoid cell populations after marrow transplantation. J Exp Med. 1985 Jun 01; 161(6):1483-502.
View in: PubMed

Origin of cell populations after bone marrow transplantation. Analysis using DNA sequence polymorphisms. J Clin Invest. 1985 Feb; 75(2):596-603.
View in: PubMed

Evidence that pluripotential stem cells form splenic colonies in humans after marrow transplantation. Transplantation. 1985 Jan; 39(1):102-5.
View in: PubMed

Cholecystokinin interacts with pregastric food stimulation to elicit satiety in the rat. Physiol Behav. 1978 Jan; 20(1):67-70.
View in: PubMed

Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J Comp Physiol Psychol. 1975 Sep; 89(7):784-90.
View in: PubMed

Absence of satiety during sham feeding in the rat. J Comp Physiol Psychol. 1974 Nov; 87(5):795-800.
View in: PubMed

Cholecystokinin does not produce bait shyness in rats. Physiol Behav. 1974 Mar; 12(3):497-8.
View in: PubMed

Vitamin D and citrate synthesis. Arch Biochem Biophys. 1959 Apr; 81(2):340-5.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top